Dr Reddy's confirms Thailand approval for gonorrhoea drug NUZOLVENCE

NSE sought clarification on a Business Standard article saying Dr Reddy's antibiotic got Thailand approval six months after US nod. The company confirmed the headline is correct: Thai FDA has approved NUZOLVENCE (zoliflodacin), a first-in-class gonorrhoea antibiotic, developed jointly with GARDP. The US authorization came about six months earlier, with a joint press release issued on July 27, 2026. The company told the exchange there is no undisclosed material information and no material financial impact from the news.